Figure 3 from Olaparib and Ceralasertib (AZD6738) in Patients with Triple-Negative Advanced Breast Cancer: Results from Cohort E of the plasmaMATCH Trial (CRUK/15/010)Alistair Ring,Lucy S. Kilburn,Alex Pearson,Laura Moretti,Angelica Afshari-Mehr,Andrew M. Wardley,Bora Gurel,Iain R. Macpherson,Ruth Riisnaes,Richard D. Baird,Sue Martin,Rebecca Roylance,Hannah Johnson,Ana Ferreira,Matthew C. Winter,Kathryn Dunne,Ellen Copson,Tamas Hickish,Russell Burcombe,Kat Randle,Violeta Serra,Alba Llop-Guevara,Judith M. Bliss,Nicolas C. Turnercrossref(2023)引用 0|浏览10暂无评分摘要Activity according to biomarker subgroups: confirmed response rate.更多查看译文AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要